
Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist - Pipeline Insight, 2024
Description
Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist - Pipeline Insight, 2024
DelveInsight’s, Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist: Overview
Fibroblast growth factors (FGF) and their tyrosine kinase receptors (FGFR) support cell proliferation, survival and migration during embryonic development, organogenesis and tissue maintenance and their deregulation is frequently observed in cancer development and progression. Consequently, increasing efforts are focusing on the development of strategies to target FGF/FGFR signaling for cancer therapy. Fibroblast growth factors (FGF) and their tyrosine kinase receptors (FGFR) regulate important cellular processes such as cell proliferation, survival and migration during embryonic development, organogenesis and tissue maintenance.
FGFR4 deletion does not lead to an embryonic lethal phenotype suggesting the possibility that its inhibition in cancer therapy might not cause grave adverse effects. The FGFR4 kinase domain differs sufficiently from those of FGFRs1-3 to permit development of highly specific inhibitors. The oncogenic impact of FGFR4, however, is not undisputed, as the FGFR4-mediated hormonal effects of several FGF ligands may also constitute a tissue-protective tumor suppressor activity especially in the liver.
""Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist pipeline landscape is provided which includes the disease overview and Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist treatment guidelines. The assessment part of the report embraces, in depth Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence R&D Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist. The therapies under development are focused on novel approaches to treat/improve Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist.
Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Emerging Drugs
- Pemigatinib: Incyte Corporation
- H3B-6527: H3 biomedicine
Further product details are provided in the report……..
Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist: Therapeutic Assessment
This segment of the report provides insights about the Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Molecule Type
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist drugs.
Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Report Insights
- Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist drugs?
- How many Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist and their status?
- What are the key designations that have been granted to the emerging drugs?
- H3 Biomedicine
- AiViva BioPharma
- Incyte Corporation
- Helsinn
- Astellas Pharma
- Taiho Oncology
- Eli Lilly and Company
- H3B 6527
- Lenvatinib
- Pemigatinib
- Infigratinib
- ASP-5878
- Futibatinib
- LY 2874455
Table of Contents
65 Pages
- Introduction
- Executive Summary
- Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist: Overview
- What is Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist?
- Types of Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist
- Causes
- Epidemiology and Risk Factors
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Infigratinib: Helsinn
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Pemigatinib: Incyte Corporation
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- H3B 6527: H3 Biomedicine
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Comparative Analysis
- ASP5878: Astellas Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Key Companies
- Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Key Products
- Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist- Unmet Needs
- Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist- Market Drivers and Barriers
- Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist- Future Perspectives and Conclusion
- Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Analyst Views
- Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.